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The International Circumpolar Surveillance System is a 
population-based surveillance network for invasive bacterial 
disease in the Arctic. The 7-valent pneumococcal conjugate 
vaccine (PCV7) was introduced for routine infant vaccina-
tion in Alaska (2001), northern Canada (2002–2006), and 
Norway (2006). Data for invasive pneumococcal disease 
(IPD) were analyzed to identify clinical ﬁ  ndings,  disease 
rates, serotype distribution, and antimicrobial drug suscepti-
bility; 11,244 IPD cases were reported. Pneumonia and bac-
teremia were common clinical ﬁ  ndings. Rates of IPD among 
indigenous persons in Alaska and northern Canada were 43 
and 38 cases per 100,000 population, respectively. Rates in 
children <2 years of age ranged from 21 to 153 cases per 
100,000 population. In Alaska and northern Canada, IPD 
rates in children <2 years of age caused by PCV7 serotypes 
decreased by >80% after routine vaccination. IPD rates are 
high among indigenous persons and children in Arctic coun-
tries. After vaccine introduction, IPD caused by non-PCV7 
serotypes increased in Alaska.
T
he International Circumpolar Surveillance (ICS) proj-
ect was established in 1999 to create an infectious dis-
ease surveillance network throughout Arctic countries and 
territories. The project initially focused on invasive bac-
terial diseases caused by Streptococcus pneumoniae, Hae-
mophilus inﬂ  uenzae, Neisseria meningitidis, and groups A 
and B streptococci. In 1999, the project integrated prospec-
tive population-based surveillance data for invasive pneu-
mococcal disease (IPD) from the US Arctic (Alaska) and 
northern Canada (1). Subsequently, the ICS network ex-
panded to include Greenland in 2000, Iceland, Norway, and 
Finland in 2001, and northern Sweden in 2003. All north-
ern circumpolar countries (north of latitude 60°N), with the 
exception of Russia, participate in ICS.
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IPD was of interest to the ICS in part because it is one 
of the leading causes of pneumonia and meningitis among 
indigenous persons of the circumpolar north. Incidence 
rates of IPD are higher among indigenous persons than 
among nonindigenous persons (2–6). The proportion of in-
digenous persons in Alaska and northern Canada <5 years 
of age is 11% and 12%, respectively. In Alaska, the 7-va-
lent pneumococcal conjugate vaccine (PCV7) was made 
available to all children through a statewide immunization 
program. Data indicate that 92.6% of indigenous children 
and 64.6% of non-Hispanic white children in Alaska re-
ceived >3 doses of PCV7 from July 2003 through June 
2004, respectively. Routine use of PCV7 began in some 
areas of northern Canada in 2002. Other areas of northern 
Canada implemented PCV7 programs during 2003–2006. 
Scant data exist on vaccine coverage in northern Canada. 
However, neighboring Canadian provinces outside the 
ICS network, such as Alberta, have vaccine coverage rates 
>90% (www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05pdf/
cdr3106.pdf). Routine use of PCV7 began in Norway in 
2006. PCV7 is not currently included in the routine infant 
immunization schedule in Greenland, Iceland, northern 
Sweden, or Finland.
We analyzed IPD data collected from January 1999 
through December 2005. The purpose of the study was to 
determine rates of disease by country, common clinical 
ﬁ  ndings, risk factors, serotype distribution, antimicrobial 
drug susceptibility patterns, and changes in disease rates 
with vaccine use.
Methods
In the participating regions, clinical laboratories send 
S. pneumoniae isolated from a normally sterile site to re-
gional reference laboratories (Table 1). Reference labo-
ratories conﬁ  rm the identity, determine the serotype, and 
test for antimicrobial drug susceptibility of each isolate. 
Laboratory, demographic, and clinical data are collected 
for each invasive case of S. pneumoniae, and these data are 
forwarded to the Arctic Investigations Program (AIP) of 
the Centers for Disease Control and Prevention (CDC) in 
Anchorage, Alaska, the coordinating center for ICS.
Population distribution and land area vary widely 
among participating regions. Populations range from 
≈57,000 persons in Greenland to >5 million persons in 
Finland. Land areas range from 102,968 km2 for Iceland 
to 4,506,600 km2 for northern Canada (Table 1). Regions 
with the largest land areas (Alaska, Greenland, and north-
ern Canada) have populations scattered in remote, small 
communities often not connected by road to urban centers. 
Remote populations in Scandinavia and Iceland are better 
connected to larger urban communities.
A case-patient with IPD was deﬁ  ned as a resident of 
the surveillance area from whom S. pneumoniae was iso-
lated from a normally sterile site, including blood, cere-
brospinal ﬂ  uid, pleural ﬂ  uid, peritoneal ﬂ  uid, or joint ﬂ  uid. 
Population denominator data for the regions were obtained 
from the Statistics Canada Website (www.statcan.ca), the 
Alaska Department of Labor and Workforce Development 
Website (www.labor.state.ak.us), the Statistics Greenland 
Website (www.statgreen.gl), the Statistics Iceland Website 
(www.hagstofa.is), the Statistics Norway Website (www.
ssb.no), the Statistics Sweden Website (www.scb.se), and 
the Statistics Finland Website (www.stat.ﬁ   ). This study 
covers a 7-year surveillance period from January 1999 
through December 2005.
Epidemiologic Data
Alaska and Northern Canada
Initial identiﬁ  cation of a case of IPD results in a report 
to local public health personnel who complete standardized 
data collection forms (bacterial disease surveillance form 
[BDSF]) that include demographic, clinical, and risk factor 
information, and pertinent immunization history (www.cdc.
gov/ncidod/aip/research/ics/forms.html). All laboratory and 
case-related data are forwarded without identiﬁ  ers by fax 
and mail to the ICS coordinator at AIP in Anchorage, Alas-
ka, where they are entered into a database and analyzed.
Greenland, Iceland, Norway, 
Northern Sweden, and Finland
End of year summary data are submitted electronically 
to the ICS coordinator at AIP in Anchorage, where they 
are entered into a database. Greenland and Iceland use the 
BDSF. Norway, northern Sweden, and Finland use other 
instruments.
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Table 1. Demographics of countries participating in the study 
Characteristic Alaska Northern Canada  Greenland  Iceland Norway 
Northern 
Sweden  Finland
Mean population  641,720 132,956 56,617 288,035 4,565,943 252,729 5,215,791
% Indigenous  19 59 Unknown  Unknown  <1 <5 <1
Region size, km
2 1,518,807 4,506,600 2,131,863 102,968 323,760 160,580 339,290
No. participating 
laboratories
23 14 15 10 33 1 23
Location of reference 
laboratories
Anchorage Edmonton,
Montreal, Winnipeg 
Nuuk,
Copenhagen 
Reykjavik Oslo, 
Tromso 
Stockholm OuluICS for Invasive Pneumococcal Disease
Laboratory Data
Isolates were serotyped by the Quellung reaction 
(Alaska, northern Canada, Greenland, Norway, and north-
ern Sweden), counter-immunoelectrophoresis (Finland), or 
coagglutination (Iceland). Antimicrobial drug susceptibil-
ity testing was performed by microbroth dilution (Alaska 
and northern Canada), agar dilution (Greenland and Fin-
land), or disk diffusion (Iceland, Norway, and northern 
Sweden). A laboratory quality control program has been in 
place since the program’s inception (7).
Statistical Analysis
Data were double-entered into Paradox version 10.0 
(Corel, Ottawa, Ontario, Canada), and analyzed by using 
EpiInfo version 6.04b (CDC, Atlanta, GA, USA), SAS ver-
sion 8.0 (SAS Institute, Cary, NC, USA), and StatXact ver-
sion 6.0 (Cytel Corporation, Cambridge, MA, USA). For 
Alaska, we compared disease rates by using 1999–2000 
as the baseline period and 2001–2005 as the postvaccine 
period. For northern Canada, we used 1999–2002 as the 
baseline period and 2003–2005 as the vaccine implementa-
tion period. Standardized incidence rates were reported by 
using World Health Organization 2000 population standard 
and the age groups of <1, 2–19, 20–64, and >65 years. Sta-
tistical differences in rates between periods and between 
countries were assessed by using a 2-sample Poisson test. 
Trends in IPD incidence rates among children <2 years of 
age were assessed by using Poisson regression; p values are 
exact when appropriate.
Results
Descriptive Epidemiology
Over the 7-year surveillance period, 11,244 cases of 
IPD were detected among the 7 participating countries; 
4,921 (53%) were in male patients. Of the 5,896 case-pa-
tients for whom outcome was reported, 569 died (case-fa-
tality rate 10%). Median age of case-patients was 57 years 
and varied by country (Table 2). Among countries that did 
not use PCV7 during the study period, overall crude IPD 
incidence rates ranged from 11.6 in northern Sweden (age 
standardized rate 9.1) to 21.0 in Norway (age standardized 
rate 16.2) (Table 3).
Annualized age-speciﬁ  c incidence rates over the entire 
surveillance period were highest in children <2 years of age 
and the elderly (Tables 3, 4). Within each country, rates 
were highest in children <2 years of age except for Norway 
and northern Sweden, where rates were slightly higher in 
the elderly.
Race and ethnicity data were only available from 
Alaska and northern Canada. Over the entire surveillance 
period, annualized rates of disease were higher in Alaska 
Native (indigenous) persons (43.1 cases/100,000/year) 
than in nonindigenous persons (9.8 cases) (relative risk 
[RR] 4.4, 95% conﬁ  dence interval [CI] 3.8–5.1). Increased 
risk for IPD was similar in northern Canada (RR 3.6, 95% 
CI 2.6, 5.2) with an annualized overall rate of 36.0 cas-
es/100,000 among Canadian indigenous persons and 9.9 
cases/100,000 among nonindigenous persons. Among chil-
dren <2 years of age, increased RR for indigenous versus 
nonindigenous children was 6.5 in Alaska (95% CI 4.5, 9.4; 
indigenous 249.9 cases/100,000/year, nonindigenous 38.3 
cases/100,000/year) and 2.3 in Canada (95% CI 1.0, 5.2; 
indigenous 170.7 cases/100,000/year, nonindigenous 74.7 
cases/100,000/year).
Incidence Rates (All Serotypes) in 
Countries Using PCV7
In Alaska, incidence of IPD among all age groups de-
creased from 20.6 cases in the prevaccine period (1999–
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Table 2. Characteristics of persons with invasive pneumococcal disease, by country* 
Characteristic
Alaska,
1999–2005,
n = 769 
Northern 
Canada,
1999–2005,
n = 251 
Greenland, 
2000–2005,
n = 69 
Iceland,
2000–2005,
n = 274 
Norway,  
2000–2005,
n = 5,744 
Northern 
Sweden, 
2003–2005,
n = 88 
Finland,
2000–2005,
n = 4,049 
Median age (range)  41.6
(1 mo–100 y) 
30.2
(0 mo– 83 y) 
44.7
(0 mo–91 y) 
53.2
(1 mo–98 y) 
63.2
(0 mo–99 y) 
65.8
(9 mo–98 y) 
54.2
(0 mo–100 y) 
No. males (%)  423 (55)  149 (60)  37 (54)  145 (53)  2,856 (50)  40 (45)  2,271 (56) 
No. indigenous (%)  372 (48)  191 (84)†  NA NA NA NA NA
No. hospitalized (%)  585 (77)‡  201 (87)‡  62 (100)‡  NA 5,567 (99)‡  NA NA
Duration of 
hospitalization, d, 
median (minimum–
maximum) 
4 (0–188)  5 (0–77)  9 (0–131)  NA NA NA NA
No. deaths (%)  96 (13)§  11 (5)§  13 (20)§  30 (27)§  419 (9)§  NA NA
*NA, not available. 
†Ethnicity data missing from 24 (northern Canada) cases. Denominator = 227. 
‡Hospitalization data missing for 9 (Alaska), 21 (northern Canada), 7 (Greenland), and 127 (Norway) cases. Denominators are 760, 230, 62, and 5,617, 
respectively. 
§Death information missing for 10 (Alaska), 21 (northern Canada), 3 (Greenland), 161 (Iceland), and 1,1016 (Norway) cases. Denominators are 759, 230, 
66, 113, and 4,728, respectively. INTERNATIONAL POLAR YEAR  RESEARCH
2000) to 15.8 cases/100,000 persons in the postvaccine pe-
riod (2001–2005; p = 0.0004). Among Alaskan children <2 
years of age, incidence of IPD decreased from 173.5 cases 
in the pre–conjugate vaccine period to 79.2 cases/100,000 
children in the postvaccine period (p<0.0001). Similarly, in 
northern Canada, incidence of IPD among all age groups 
decreased from 31.0 cases/100,000 persons in the prevac-
cine period (1999–2002) to 21.6 cases/100,000 persons in 
the vaccine implementation period (2003–2005; p = 0.007) 
(Table 4). Among northern Canadian children <2 years of 
age, incidence of IPD had been decreasing in the 2 years 
before PCV7 use (Figure). The incidence of IPD decreased 
from 185.6 cases/100,000 children in the prevaccine period 
(1999–2002) to 110.0 cases/100,000 children in the vaccine 
implementation period (2003–2005), However, this decrease 
was not statistically signiﬁ  cant (p = 0.10) (Table 4).
In Alaska, incidence of IPD among all indigenous 
persons decreased from 56.0 cases/100,000 persons in the 
pre–conjugate vaccine period (1999–2000) to 38.1 cas-
es/100,000 persons in the postvaccine period (2001–2005; 
p = 0.0003). Among Alaskan indigenous children <2 years 
of age, incidence decreased from 440.6 in the pre–con-
jugate vaccine period to 177.5 in the postvaccine period 
(p<0.0001). Similarly, in northern Canada, incidence of 
IPD among indigenous persons decreased from 44.2 cas-
es/100,000 persons in the prevaccine period (1999–2002) 
to 25.0 cases/100,000 persons in the vaccine implemen-
tation period (2003–2005; p = 0.0005). Among Canadian 
indigenous children <2 years of age, incidence decreased 
from 229.3/100,000 persons in the prevaccine period to 
92.6/100,000 persons in the vaccine implementation period 
(2003–2005; p = 0.01) (Table 4).
PCV7 Serotype–speciﬁ  c Incidence Rates 
in Countries Using PCV7
In Alaska, the incidence of serotypes contained in 
PCV7 in all age groups decreased from 9.6 cases/100,000 
persons in the pre–conjugate vaccine period (1999–2000) 
to 3.4 cases/100,000 persons in the postvaccine period 
(2001–2005; p<0.0001). PCV7 serotype–speciﬁ  c  inci-
dence among Alaska children <2 years decreased from 
128.3 cases/100,000 persons in the pre–conjugate vaccine 
period to 15.5 cases/100,000 persons in the postvaccine pe-
riod (p<0.0001). Among older age groups in Alaska (2–19, 
20–64, and >65 years), decreases in PCV7 serotype–spe-
ciﬁ  c incidence also occurred. However, this decrease was 
not statistically signiﬁ  cant in persons 20–64 years of age 
(Table 4). In northern Canada, incidence of serotypes in 
PCV7 in all age groups decreased from 12.6 cases/100,000 
persons in the pre–conjugate vaccine period (1999–2002) 
to 3.8 cases/100,000 persons in the vaccine implementation 
period (2003–2005; p<0.0001) (Table 4). PCV7 serotype–
speciﬁ  c incidence among northern Canadian children <2 
years of age decreased from 128.9 cases/100,000 children 
in the prevaccine period to 20.6 cases/100,000 children in 
the vaccine implementation period (p = 0.0008; Table 4). 
Decreases in age-speciﬁ  c incidence of PCV7 disease also 
occurred among older age groups in northern Canada ex-
cept among persons >65 years of age (Table 4). Among 
indigenous persons in Alaska and northern Canada, PCV7 
serotype–speciﬁ  c incidence showed a statistically signiﬁ  -
cant decrease from the prevaccine period to the postvaccine 
implementation period (Table 4).
In Alaska, non-PCV7 serotype–speciﬁ  c  incidence 
among all age groups increased from 8.3 cases/100,000 
persons in the pre–conjugate vaccine period (1999–2000) 
to 10.5 cases/100,000 persons in the postvaccine period 
(2001–2005; p = 0.04). Non-PCV7 serotype–speciﬁ  c inci-
dence among Alaskan children <2 years of age increased 
from 27.7 cases/100,000 children in the pre–conjugate vac-
cine period to 59.0 cases/100,000 children in the postvac-
cine period (p = 0.03). In northern Canada, non-PCV7 se-
rotype–speciﬁ  c incidence among all age groups remained 
relatively stable at 17.1 cases/100,000 persons in the pre-
vaccine period (1999–2002) and 16.8 cases/100,000 per-
sons in the vaccine implementation period (2003–2005; 
p = 0.94) (Table 4). Non-PCV7 serotype–speciﬁ  c  inci-
dence among northern Canadian children <2 years of age 
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Table 3. Annualized crude and standardized incidence rates (per 100,000 persons) of IPD by countries not using 7-valent 
pneumococcal conjugate vaccine* 
Statistic or age group 
Greenland  
(2000–2005) 
Iceland
(2000–2005) 
Norway  
(2000–2005) 
Northern Sweden 
(2003–2005) 
Finland
(2000–2005) 
Total no. cases  69 274 5,744 88 4,049
Age-specific annualized incidence rates (no. cases) 
  <2 y  77.4 (8)  89.8 (45)  50.0 (355)  21.1 (3)  52.3 (367) 
  2–19 y  4.8 (5)  6.8 (32)  4.9 (312)  0.0 (0)  5.0 (346) 
  20–64 y  25.5 (53)  8.9 (90)  14.5 (2,352)  9.3 (41)  10.9 (2,057) 
>65 y  16.6 (3)  53.1 (107)  66.7 (2,725)  30.9 (44)  26.6 (1,279) 
Crude annualized incidence (all 
ages)
20.3 15.9 21.0 11.6 12.9
Annualized age standardized 
incidence†
19.8 14.6 16.2 9.1 11.6
*IPD, invasive pneumococcal disease, 
†Rates adjusted to 2000 World Health Organization world standard population estimates. ICS for Invasive Pneumococcal Disease
increased from 41.2 cases/100,000 children in the pre–con-
jugate vaccine period (8 cases) to 75.6 cases/100,000 chil-
dren in the vaccine implementation period (11 cases). How-
ever, this increase was not statistically signiﬁ  cant (p = 0.25; 
Table 4). Among indigenous persons in Alaska, non-PCV7 
serotype–speciﬁ   c incidence demonstrated a statistically 
signiﬁ  cant increase from the prevaccine to the postvaccine 
period. However, this trend was not seen among Canadian 
indigenous persons (Table 4).
Incidence Rates (All Serotypes) in 
Countries Not Using PCV7
IPD rates among children <2 years of age increased in 
Norway and Finland (p<0.01 and p = 0.04, respectively). 
A slight increase was also seen in Iceland, but this increase 
was not statistically signiﬁ  cant (p = 0.56). Because of low 
numbers of cases, rates in Greenland were unstable but 
showed no statistically signiﬁ  cant change (Figure).
Serotype Distribution
Several serotypes were common among Arctic coun-
tries participating in ICS, including 14, 4, 7F, and 6B. 
Among the 4 most prevalent serotypes in the Arctic, 3 are 
found in PCV7. 
In Alaska, before vaccine use, the 5 most common 
serotypes were 14 (17%), 4 and 7F (9%), 9V (8%), 19F 
(6%), and 6B (6%). In the prevaccine period among chil-
dren <2 years of age, 82% of serotypes in Alaska were in 
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Table 4. Rates/100,000 cases of IPD in Alaska and Northern Canada before and after introduction of PCV7*  
Alaska Northern Canada 
Group 
Prevaccine
(1999–2000) 
Postvaccine
(2001–2005)  p value 
Prevaccine
(1999–2002) 
Vaccine
implementation
(2003–2005)  p value 
Total no. cases  257 512 NA 165 86 NA
All ages, y  20.6 (257)  15.8 (512)  0.0004 31.0 (165)  21.6 (86)  0.007
  <2  173.5 (69)  79.2 (82)  <0.0001 185.6 (36)  110.0 (16)  0.10
  2–19  10.7 (40)  6.6 (64)  0.02 22.9 (41)  9.7 (13)  0.009
  20–64  13.7 (104)  14.1 (278)  0.82 23.8 (74)  18.8 (44)  0.24
   65 57.9 (44)  44.5 (88)  0.17 64.4 (14)  73.5 (12)  0.84
Indigenous, all ages  56.0 (133)  38.1 (239)  0.0003 44.2 (134)  25.0 (57)  0.0005
  <2 y  440.6 (47)  177.5 (50)  <0.0001 229.3 (33)  92.6 (10)  0.01
Nonindigenous, all ages  12.3 (124)  10.4 (273)  0.13 9.6 (20)  10.2 (16)  0.86
  <2 y  75.7 (22)  42.5 (32)  0.05 65.4 (3)  87.2 (3)  1.00
PCV 7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F)† 
All ages, y  9.6 (120)  3.4 (110)  <0.0001 12.6 (67)  3.8 (15)  <0.0001
  <2  128.3 (51)  15.5 (16)  <0.0001 128.9 (25)  20.6 (3)  0.0008
  2–19  5.6 (21)  1.6 (16)  0.0003 8.4 (15)  1.5 (2)  0.01
  20–64  4.1 (31)  2.8 (55)  0.09 7.1 (22)  1.7 (4)  0.005
≥65 22.4 (17)  11.6 (23)  0.05 23.0 (5)  36.8 (6)  0.55
Indigenous, all ages  24.9 (59)  4.9 (31)  <0.0001 17.1 (52)  3.5 (8)  <0.0001
  <2 y  318.7 (34)  21.3 (6)  <0.0001 159.8 (23)  9.3 (1)  0.0001
Nonindigenous, all ages  6.0 (61)  3.0 (79)  <0.0001 6.2 (13)  3.2 (5)  0.24
  <2 y  58.5 (17)  13.3 (10)  <0.0001 43.6 (2)  29.1 (1)  1.00
Non-PCV7 serotypes† 
All ages, y  8.3 (104)  10.5 (341)  0.04 17.1 (91)  16.8 (67)  0.94
<2 27.7 (11)  59.0 (61)  0.03 41.2 (8)  75.6 (11)  0.25
2–19 3.5 (13)  4.1 (40)  0.65 14.5 (26)  7.4 (10)  0.09
20–64 7.3 (55)  9.6 (189)  0.07 15.4 (48)  16.7 (39)  0.75
>65 32.9 (25)  25.8 (51)  0.31 41.4 (9)  36.8 (6)  1.00
Indigenous, all ages  20.2 (48)  29.8 (187)  0.01 25.4 (77)  20.2 (46)  0.24
  <2 y  65.6 (7)  145.6 (41)  0.05 48.6 (7)  74.1 (8)  0.44
Nonindigenous, all ages   5.5 (56)  5.9 (154)  0.71 2.9 (6)  7.0 (11)  0.09
  <2 y  13.8 (4)  26.6 (20)  0.26 21.8 (1)  58.1 (2)  0.58
Penicillin nonsusceptible IPD, all serotypes‡ 
All ages  4.0 (50)  2.1 (68)  0.0004 1.5 (8)  0.8 (3)  0.37
  <2 y  62.9 (25)  21.3 (22)  <0.0001 10.3 (2)  0.0 (0)  0.51
Cotrimoxazole nonsusceptible IPD, all serotypes‡ 
All ages  5.6 (70)  3.0 (96)  0.0003 2.6 (14)  1.8 (7)  0.50
  <2 y  90.5 (36)  25.1 (26)  <0.0001 15.5 (3)  13.7 (2)  1.00
*IPD, invasive pneumococcal disease, PCV7, 7-valent pneumococcal conjugate vaccine; NA, not available. Values in parentheses are no. cases. 
†Serotype available for 675 (88%) of 769 Alaska isolates and 240 (96%) of 251 Northern Canada isolates. 
‡Antimicrobial drug susceptibility available for 677 (88%) of 769 Alaska isolates and 236 (94%) of 251 northern Canada isolates.INTERNATIONAL POLAR YEAR  RESEARCH
PCV7. After introduction of PCV7 (2001–2005), 21% of 
serotypes were in PCV7 (Table 5), and among all ages 19A 
(11%) is now the most prevalent serotype, followed by 4 
(8%), 12F (8%), 3/7F/8 (7%), and 14 (6%).
In northern Canada, the 5 most prevalent serotypes be-
fore PCV7 use were 1 (34%), 14 (11%), 4 (9%), 8 (8%), 
and 6B/9V (6% each). In the prevaccine period, among 
children <2 years of age, 76% of serotypes in northern 
Canada were in PCV7. During the vaccine implementation 
period (2003–2005), 21% of serotypes in northern Cana-
da were in PCV7 (Table 5). Serotype distribution (all age 
groups combined) has changed; however, serotype 1 (24%) 
continues to be the most prevalent serotype, followed by 
8 (11%), 3 (7%), 10A/18C/22F (6%), and 6B (5%). Two 
regions in northern Canada had outbreaks of serotype 1 
during the surveillance period, which may have affected 
relative frequencies of serotypes (8–10).
Antimicrobial Drug Resistance
Alaska had the highest proportion of isolates nonsus-
ceptible to antimicrobial drugs among ICS regions report-
ing these data. With use of PCV7, the proportion of isolates 
nonsusceptible to penicillin among children <2 years of age 
decreased from 40% to 29% and from 6% to 0% (prevac-
cine to postvaccine period) in Alaska and northern Canada, 
respectively (Table 6). Rates of IPD with penicillin-nonsus-
ceptible isolates decreased from 62.9 cases/100,000 chil-
dren to 21.3 cases/100,000 children (p<0.0001) in Alaska, 
and rates decreased from 10.3 cases/100,000 children to 0 
cases/100,000 children (p = 0.51) in northern Canada (Ta-
ble 4). However, in 2 countries currently not using PCV7, 
comparison of 2 periods (2000–2002 and 2003–2005) 
showed that rates of IPD with penicillin-nonsusceptible 
isolates increased from 0.6 cases to 1.7 cases/100,000 per-
sons (p = 0.04 for all ages, Iceland), and from 0.5 to 1.0 
(p<0.0001, all ages. Finland). In both of these countries, the 
proportion of isolates that were nonsusceptible to penicillin 
also increased (Iceland, 5% [5/106] to 12% [15/130], p = 
0.05; Finland, 4% [82/1,850] to 7% [154/2,199]; p<0.01).
Since routine use of PCV7, the proportion of isolates 
nonsusceptible to cotrimoxazole, erythromycin, ceftriax-
one, and penicillin decreased in Alaska. The same trend 
was not observed in northern Canada, where rates of anti-
microbial drug resistance were much lower than in Alaska 
(Table 6).
Clinical Findings
Data on clinical ﬁ   ndings were available for Alaska, 
northern Canada, Greenland, and Norway. Bacteremic pneu-
monia was the most common clinical ﬁ  nding (range 45%–
65%), followed by bacteremia alone (range 16%–24%) and 
bacteremic meningitis (Table 7). Limited clinical data were 
available for Iceland and northern Sweden but were not in-
cluded. Clinical data were not available for Finland.
Risk Factors and Medical Conditions in 
Persons ≥18 Years of Age
Data on risk factors and medical conditions were avail-
able for Alaska and northern Canada. Among adults with a 
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Figure. Annual invasive pneumococcal disease rates among 
children <2 years of age by International Circumpolar Surveillance 
System member country, 1999–2005. The p values are for trend.
Table 5. Most prevalent serotypes in 6 countries reporting Streptococcus pneumoniae type to ICS and proportion of isolates covered 
by PCV7 and PCV13 vaccines* 
Alaska Canada
Rank
Pre-PCV7,
1999–2000,
n = 224 
Post-PCV7,
2001–2005,
n = 453 
Pre-PCV7,
1999–2002,
n = 158 
Post-PCV7,
2003–2005,
n = 82 
Greenland, 
n = 60 
Iceland,
n = 269 
Norway,  
n = 291 
Finland,
n =  3,947 
1 14 (17%)  19A (11%)  1 (34%)  1 (24%)  1 (22%)  7 (20%)  4, 14 (18%)  14, 4 (12%) 
2 4, 7F (9%)  4 (8%)  14 (11%)  8 (11%)  12F (15%)  14 (12%)  9 (11%)  9V (8%) 
3 9V (8%)  12F (8%)  4 (9%)  3 (7%)  4 (12%)  23 (12%)  6 (9%)  3, 23F, 7F 
(7%)
4 19F (6%)  3, 7F, 8 (7%)  8 (8%)  10A, 18C,
22F (6%) 
22F (8%)  19 (10%)  23 (8%)  6B (6%) 
5 6B (6%)  14 (6%)  6B, 9V (6%)  6B (5%)  3 (7%)  9 (10%)  7 (7%)  19A, 19F (4%)
Proportion of serotyped isolates covered by PCV7 and PCV13 vaccines (<2 y of age) 
PCV7 82% (51/62)  21% (16/77)  76% (25/33)  21% (3/14)  50% (3/6)  51% (23/45)  37% (10/27)  NA
PCV13 92% (57/62)  57% (44/77)  94% (31/33)  43% (6/14)  83% (5/6)  60% (27/45)  56% (15/27)  NA
*ICS, International Circumpolar Surveillance; PCV7, 7-valent pneumococcal conjugate vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F); PCV13, 13-
valent pneumococcal conjugate vaccine (7 PCV7sero types plus 1, 3, 5, 6A, 7F, and 19A); NA, not available. ICS for Invasive Pneumococcal Disease
diagnosis of IPD in the North American Arctic, 40%–44% 
had a history of smoking, 37%–39% had a history of al-
cohol abuse, and 19%–27% had a history of chronic lung 
disease (Table 8).
Discussion
Our data show that cases of IPD continue to occur 
throughout Arctic countries with highest rates among 
children <2 years of age, adults >65 years of age, and in-
digenous persons of the North American Arctic. The rate 
of IPD with PCV7 serotypes in children <2 years of age 
decreased dramatically after routine vaccination in Alaska 
(128.3 to 15.5/100,000) and northern Canada (128.9 to 
20.6/100,000). However, in Alaska, rates of non-PCV7 
serotypes among children <2 years of age increased (27.7 
to 59.0/100,000) during the same period. Although PCV7 
serotype–speciﬁ  c IPD rates decreased among children <2 
of age in countries that have implemented use of PCV7, 
overall rates of IPD among indigenous North American 
children remain high at 177.5 cases/100,000 and 92.6 cas-
es/100,000 in Alaska and northern Canada, respectively, 
showing persistent health disparities.
Consistent with earlier studies, IPD rates were high-
est in the prevaccine period among indigenous persons in 
Alaska and northern Canada and high among children <2 
years of age and the elderly (1,5,11–18). The relatively 
higher rates among children <2 years of age in Alaska and 
northern Canada (compared with other circumpolar coun-
tries) are primarily caused by increased rates in large indig-
enous populations (19% and 59% of the total population in 
Alaska and northern Canada, respectively), which tend to 
live under conditions of crowding, increasing environmen-
tal stress, and lower socioeconomic status. 
IPD rates in the prevaccine period among indigenous 
children ranged from 229/100,000 (northern Canada) to 
441/100,000 (in Alaska). These rates that are 4–6 times 
higher than those found among nonindigenous children in 
those regions. Indigenous persons in the circumpolar north 
have been shown to have high rates of IPD (1,2,5,15,19–
21), as have other indigenous groups such as Aboriginal 
Australians (22), White Mountain Apaches (23) and Nava-
jos in the southwestern United States (24), Maoris of New 
Zealand (25), and the bedouins of Israel (26).
Our data demonstrate that use of PCV7 in Alaska and 
northern Canada led to marked decreases in the incidence 
of IPD and PCV7 serotype–speciﬁ  c disease overall (all 
age groups combined) among indigenous persons (all age 
groups combined) and among indigenous children <2 years 
of age. Use of this vaccine has resulted in a near equal-
ization of rates of PCV7 serotype–speciﬁ  c disease among 
indigenous children <2 years of age in Alaska and northern 
Canada. Our data also show decreases in disease among 
persons >2 years of age who were not targeted to receive 
vaccine. Although some children >2 years of age may have 
received vaccine as part of vaccine catch-up programs, old-
er children and adults did not receive the vaccine. Our data 
show decreases in PCV7 serotype–speciﬁ  c disease among 
persons 20–64 years of age in northern Canada and among 
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Table 6. Proportion of isolates with nonsusceptibility to antimicrobial drugs in countries in the ICS reporting an antibiogram*
Alaska Northern Canada 
Antimicrobial
drug Age group, y
Pre-PCV7,
% (n/N) 
Post-PCV7,
% (n/N) 
Pre-PCV7,
% (n/N) 
Post-PCV7,
% (n/N) 
Iceland,
% (n/N) 
Northern 
Sweden,  
% (n/N) 
<2 58 (36/62)  34 (26/77)  9 (3/33)  17 (2/12)  35 (13/37)  100 (1/1)  Cotrimoxazole 
All ages  31 (70/224)  21 (96/453)  9 (14/158)  9 (7/78)  18
(43/234) 
12 (3/25) 
<2 42 (26/62)  13 (10/77)  0 (0/33)  8 (1/13)  26 (10/38)  0 (0/2)  Erythromycin 
All ages  21 (47/223)  8 (37/452)  1 (1/157)  5 (4/79)  9 (21/235)  6 (3/53) 
<2 23 (14/62)  5 (4/77)  6 (2/33)  0 (0/12)  0 (0/10)  NA Ceftriaxone†
All ages  11 (25/224)  1 (6/453)  4 (7/159)  0 (0/80)  0 (0/39)  NA
<2 40 (25/62)  29 (22/77)  6 (2/33)  0 (0/13)  13 (5/38)  0 (0/1)  Penicillin‡
All ages  22 (50/224)  15 (68/453)  5 (8/159)  4 (3/81)  8 (20/236)  2 (1/52) 
*ICS, International Circumpolar Surveillance; PCV7, 7-valent pneumococcal conjugate vaccine; NA, not available. 
†Greenland reported nonsusceptibility of 0% (0/38) to ceftriaxone among all ages. 
‡Greenland reported nonsusceptibility of 0% (0/41) and Finland reported nonsusceptibility of 6% (236/4,049) to penicillin among all ages. Finland reported 
nonsusceptibility of 9% (33/367) to penicillin among cases <2 y of age. 
Table 7. Clinical findings for invasive pneumococcal disease 
Findings
Alaska,
1999–2005, no. (%) 
Northern Canada, 
1999–2005, no. (%) 
Greenland,  
2000–2005, no. (%) 
Norway,  
2000–2005, no. (%) 
Pneumonia with bacteremia  466 (61)  162 (65)  36 (52)  2,598 (45) 
Sepsis 154 (20)  41 (16)  14 (20)  1,404 (25) 
Bacteremia 20 (3)  13 (5)  0 864 (15) 
Meningitis with bacteremia  53 (7)  16 (6)  14 (20)  454 (8) 
Other* 76 (10)  19 (8)  5 (7)  405 (7) 
Total 769 (100)  251 (100)  69 (100)  5,725 (100) 
*Empyema, cellulitis, necrotizing fasciitis, septic arthritis. INTERNATIONAL POLAR YEAR  RESEARCH
persons >65 years of age in Alaska. These data are con-
sistent with decreasing rates of vaccine-type IPD among 
adults in the general US population (27).
The increased rate of non-PCV7–serotype disease in 
Alaska after introduction of PCV7, primarily among indig-
enous persons, is concerning. Increases of such magnitude 
have not been observed among the general US child popu-
lation or elsewhere. However, continued vigilance is criti-
cal to monitor trends in pneumococcal disease and serotype 
distribution.
Incidence rates increased among children <2 years of 
age in 2 of 4 ICS members countries not using PCV7 over 
the study period (Norway and Finland). Norway began rou-
tine use of the vaccine among children in 2006. Continued 
collection of surveillance data will be critical in the coming 
years to assess the effect of pneumococcal vaccine, sero-
type shifts, and changes in antimicrobial drug susceptibility 
patterns.
Our data show that several serotypes (4, 6, 7, and 14) 
are common in northern circumpolar countries. Although 
serotype 1 was the most prevalent serotype in Greenland 
and northern Canada, it was not common in other circum-
polar countries. Among countries that were not using PCV7 
during the study period, ≈50% of all IPD cases in children 
<2 years of age were vaccine preventable (caused by sero-
types present in PCV7). Use of 13-valent conjugate vaccine 
(which includes all PCV7 serotypes plus serotypes 1, 3, 5, 
6A, 7F, and 19A) currently being evaluated for use in the 
United States could theoretically have prevented ≈70% of 
IPD cases among children <2 years of age.
In the 2 countries currently using PCV7 (Alaska and 
northern Canada), the proportion of penicillin-nonsuscep-
tible isolates decreased. Published data on antimicrobial 
drug resistance in Alaska, the United States, and Canada 
showed an increasing proportion of S. pneumoniae drug-re-
sistant isolates before vaccine implementation (15,28–30; 
www.cdc.gov/ncidod/aip/research/ar.html). Our data show 
a rapid decrease in the proportion of isolates resistant to 
penicillin and other antimicrobial drugs after PCV7 imple-
mentation. In the only 2 countries for which data on antimi-
crobial drug susceptibility were available and which were 
not using the vaccine (Iceland and Finland), the proportion 
of isolates resistant to penicillin increased over the study 
period.
To our knowledge, the ICS collaboration and data 
presented in this report are the ﬁ  rst population-based as-
sessment of IPD in the Arctic using similar case deﬁ  nitions 
and comparable laboratory methods. However, this study 
has several limitations. We did not collect detailed clinical 
and demographic information beyond what was available 
from medical record review and thus could not evaluate 
an extensive range of risk factors. Data on clinical ﬁ  nd-
ings, antimicrobial drug susceptibility, and risk factors are 
not collected consistently across the entire ICS network, 
and data on race/ethnicity are collected from only 2 ICS 
member countries. Because not all ICS member countries 
joined the network in the same year, the number of years 
of data available during the study period varied by country. 
In addition, limited information exists on diagnostic cultur-
ing practices of ICS member countries, which may lead to 
detection bias (milder cases more likely to be detected in 
some regions). This limitation may contribute to the wide 
variation in case-fatality rates across the ICS network. 
Finally, these data do not represent a complete picture of 
pneumococcal invasive disease in the far north because the 
Russian Federation does not participate in ICS, and data 
from only 1 region in northern Sweden are included.
The ICS project provides a broad view of IPD and 
the utility and status of prevention efforts in the Arctic. 
Demonstration of the effectiveness of PCV7 in Alaska and 
Canada and identiﬁ  cation of issues relevant for future vac-
cine development are critical for decision making. Surveil-
lance data on serotype and antimicrobial drug susceptibility 
distribution in Arctic countries provide necessary informa-
tion for assessing the potential effect of current and future 
pneumococcal vaccines. Continuing evaluation of IPD in 
the ICS network will provide data necessary to maximize 
IPD prevention efforts throughout the region.
Acknowledgments
We thank the personnel of the Public Health Agency of 
Canada, Arctic Investigations Program, Landspitali University 
Hospital, Ofﬁ  ce of Greenland’s chief medical ofﬁ  cer, Norwegian 
Institute of Public Health, National Public Health Institute of Fin-
land, Sunderby Hospital and Umea University in Sweden, Statens 
Serum Institute, the Nunavik, Cree Region, and Alaska Depart-
ments of Health for contributions to this study.
This work was supported by CDC and the Public Health 
Agency of Canada.
32  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 1, January 2008
Table 8. Risk factors and medical conditions in persons >18
years of age with invasive pneumococcal disease* 
Factor or condition 
Alaska, 1999–
2005, no. (%) 
Northern Canada, 
1999–2005, no. (%) 
Cigarette smoking  223 (44)  54 (40) 
Alcohol abuse†  201 (39)  50 (37) 
Chronic lung 
disease/asthma
139 (27)  26 (19) 
Diabetes mellitus  71 (14)  22 (16) 
Immunosuppressive 
therapy 
35 (7)  5 (4) 
Injection drug use  11 (2)  3 (2) 
Asplenia 9 (2)  4 (3) 
Total 509 (100)  135 (100) 
*Risk factors and medical conditions are not mutually exclusive. Each case
may have >1 condition reported. Data were not available for Greenland, 
Iceland, Norway, northern Sweden, or Finland. 
†Alcohol abuse was noted in the chart. ICS for Invasive Pneumococcal Disease
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